See more : AB Volvo (publ) (VOLV-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Mallinckrodt plc (MNK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mallinckrodt plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Teuton Resources Corp. (TUO.V) Income Statement Analysis – Financial Results
- ICD Co., Ltd. (040910.KQ) Income Statement Analysis – Financial Results
- E-Star Commercial Management Company Limited (6668.HK) Income Statement Analysis – Financial Results
- Kanemi Co., Ltd. (2669.T) Income Statement Analysis – Financial Results
- Lendlease Group (LLESY) Income Statement Analysis – Financial Results
Mallinckrodt plc (MNK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mallinckrodt.com
About Mallinckrodt plc
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21B | 2.21B | 2.21B | 3.16B | 3.22B | 3.22B | 3.38B | 3.35B | 2.54B | 2.21B | 2.06B | 2.02B |
| Cost of Revenue | 1.32B | 1.32B | 1.54B | 1.74B | 1.74B | 1.57B | 1.53B | 1.49B | 1.34B | 1.18B | 1.09B | 1.11B |
| Gross Profit | 891.70M | 891.70M | 669.40M | 1.42B | 1.47B | 1.66B | 1.86B | 1.85B | 1.20B | 1.03B | 964.80M | 914.90M |
| Gross Profit Ratio | 40.37% | 40.37% | 30.24% | 44.95% | 45.75% | 51.41% | 54.87% | 55.38% | 47.36% | 46.62% | 46.92% | 45.25% |
| Research & Development | 205.20M | 205.20M | 290.80M | 349.40M | 361.10M | 277.30M | 262.20M | 185.10M | 166.90M | 166.50M | 144.10M | 141.50M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 581.80M | 581.80M | 884.10M | 831.00M | 834.10M | 920.90M | 925.30M | 1.17B | 842.10M | 611.40M | 551.70M | 532.50M |
| Other Expenses | 0.00 | 22.00M | 7.40M | 63.60M | 30.90M | 6.00M | -600.00K | 8.10M | 1.80M | 800.00K | 1.00M | 2.90M |
| Operating Expenses | 787.00M | 787.00M | 1.17B | 1.18B | 1.20B | 1.20B | 1.19B | 1.35B | 1.01B | 777.90M | 695.80M | 674.00M |
| Cost & Expenses | 2.10B | 2.10B | 2.72B | 2.92B | 2.94B | 2.76B | 2.71B | 2.85B | 2.35B | 1.96B | 1.79B | 1.78B |
| Interest Income | 1.90M | 1.90M | 5.90M | 9.50M | 8.20M | 4.60M | 1.30M | 1.00M | 1.50M | 300.00K | 400.00K | 200.00K |
| Interest Expense | -222.60M | 222.60M | 261.10M | 309.00M | 370.20M | 369.10M | 384.60M | 255.60M | 82.60M | 19.50M | 500.00K | 600.00K |
| Depreciation & Amortization | 328.90M | 675.80M | 885.20M | 951.10M | 852.10M | 808.30M | 834.50M | 672.50M | 275.90M | 139.60M | 130.90M | 119.80M |
| EBITDA | -723.50M | 804.40M | 393.00M | 1.27B | 1.17B | 468.70M | 1.50B | 1.18B | 473.30M | 254.30M | 401.30M | 363.80M |
| EBITDA Ratio | -32.76% | 36.42% | 17.76% | 40.01% | 36.30% | 14.55% | 44.45% | 35.27% | 18.63% | 11.50% | 19.52% | 17.99% |
| Operating Income | -1.05B | 128.60M | -492.20M | 314.10M | -3.72B | 420.10M | 617.30M | 461.80M | -284.10M | 148.70M | 235.20M | 240.70M |
| Operating Income Ratio | -47.65% | 5.82% | -22.24% | 9.93% | -115.71% | 13.04% | 18.26% | 13.80% | -11.18% | 6.72% | 11.44% | 11.91% |
| Total Other Income/Expenses | 222.60M | -958.40M | -468.60M | -1.91B | -331.10M | -358.50M | -383.90M | -246.50M | -79.30M | -18.40M | 900.00K | 2.50M |
| Income Before Tax | -829.80M | -829.80M | -960.80M | -1.59B | -4.05B | 61.60M | 233.40M | 215.30M | -363.40M | 130.30M | 236.10M | 243.20M |
| Income Before Tax Ratio | -37.57% | -37.57% | -43.41% | -50.32% | -126.01% | 1.91% | 6.90% | 6.43% | -14.30% | 5.89% | 11.48% | 12.03% |
| Income Tax Expense | -112.40M | -106.30M | 8.90M | -584.30M | -430.10M | -1.71B | -255.60M | -92.90M | -44.80M | 70.20M | 94.80M | 86.20M |
| Net Income | -717.40M | -723.50M | -969.70M | -1.01B | -3.61B | 2.13B | 643.70M | 324.70M | -319.30M | 61.10M | 134.60M | 150.70M |
| Net Income Ratio | -32.48% | -32.76% | -43.81% | -31.85% | -112.17% | 66.25% | 19.04% | 9.70% | -12.57% | 2.76% | 6.55% | 7.45% |
| EPS | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.85 | 5.82 | 2.78 | -4.92 | 1.06 | 2.33 | 2.61 |
| EPS Diluted | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.80 | 5.77 | 2.75 | -4.92 | 1.06 | 2.33 | 2.61 |
| Weighted Avg Shares Out | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.70M | 110.60M | 115.80M | 64.90M | 57.70M | 57.70M | 57.70M |
| Weighted Avg Shares Out (Dil) | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.90M | 111.50M | 117.20M | 64.90M | 57.80M | 57.70M | 57.70M |
Mallinckrodt readies retention bonuses in event of bankruptcy filing
Mallinckrodt stock soars, after disclosure that $200 million opioid-settlement payment was delayed by a week
Mallinckrodt looking to delay $200 million opioid payment - Bloomberg News
Mallinckrodt stock falls after decision not to make interest payments, as drug maker continues to mull potential bankruptcy
Why Is Mallinckrodt (MNK) Stock Down 23% Today?
Mallinckrodt evaluating another possible bankruptcy filing as $200 million opioid settlement pay comes due
Drugmaker Mallinckrodt says lenders propose another bankruptcy filing
Drugmaker Mallinckrodt may file for bankruptcy again -WSJ
Mallinckrodt to Report Earnings Results for First Quarter 2023
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation – MNK
Source: https://incomestatements.info
Category: Stock Reports